Contract drug developer AMRI bolstered its client roster with three new agreements making use of its R&D, manufacturing and marketing divisions.
Catalent Pharma Solutions is loaning out one of its drug development platforms to Roche in a heavily back-loaded deal, signing on to reap as much as $619 million.
Medtronic stealthily acquired the OsteoCool RF Ablation System from Baylis Medical last month. Now, the medical device giant has launched the cooled radiofrequency (RF) ablation tech in the U.S. after it received 510(k) clearance from the FDA in November. Baylis and Medtronic have also partnered for further innovations to the system.
German pharma giant Boehringer Ingelheim is wagering up to $262 million on a discovery-stage project with the struggling Arena Pharmaceuticals, hoping to spotlight new treatments for central nervous system disorders.
Dexcom offered investors a glimpse of its high-profile partnership with Google Life Sciences to develop a next-generation continuous glucose monitor that would be tiny, disposable and affordable for the world's masses of Type 2 diabetics. A product isn't expected to result for another 5 years or so--but Dexcom has committed $40 million to the project, making this its largest R&D expense, the company said at this year's J.P. Morgan Healthcare Conference in San Francisco.
Israeli drug developer BioLineRx is partnering with Merck to see whether its in-development cancer therapy can work in tandem with an approved treatment that taps the power of the immune system, joining a long list of clinical partners.
A partnership dispute over co-promotion duties between LG Life Sciences and Sanofi-Aventis Korea, the local affiliate of France's Sanofi, threatens to spill over into the courts if the two companies cannot settle their differences.
Osaka-based Takeda Pharmaceutical has lined up another gastrointestinal deal, this time to work with Montreal-based enGene to develop new treatments.
Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape gets more and more competitive.
In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.